Supporting KalVista’s NDA Submission for a Novel HAE Treatment Case Study Supporting KalVista’s NDA Submission for a Novel HAE Treatment To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…Danielle PillsburyNovember 12, 2025
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Case Study Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…CertaraNovember 10, 2025
Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns On-Demand Webinar Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns Improve pediatric drug development with Certara’s Pediatric Practice, MIDD expertise for PIPs/PSPs, dose selection, regulatory…CertaraNovember 10, 2025
Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient On-Demand Webinar Failure to Launch: Building Smarter Strategies to Get the Right Drug to the Right Patient Watch the on-demand webinar on avoiding drug launch failure. Learn how smarter development, evidence, and…CertaraNovember 6, 2025
Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation Publication Quantitative Model-Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation This study demonstrates how model-informed approaches can improve dose selection decisions when direct clinical comparisons…CertaraNovember 5, 2025
Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights On-Demand Webinar Delivering on Deadline: Navigating Regulatory Submissions with Pharmacometrics Insights Watch this on-demand webinar to learn how pharmacometrics supports NDA, BLA, and global regulatory submissions.…CertaraNovember 3, 2025
AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success On-Demand Webinar AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…CertaraOctober 21, 2025
Streamlining PK/PD Reporting: A Smarter Approach to Generating Tables, Figures and Listings Blog Streamlining PK/PD Reporting: A Smarter Approach to Generating Tables, Figures and Listings Discover how TFL Studio accelerates PK/PD reporting. Create audit-ready tables, figures, and listings faster with…CertaraOctober 16, 2025
Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results Publication Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…CertaraOctober 15, 2025
PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software Live Events PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software – Scarman, Coventry, UKCertaraOctober 14, 2025